{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vestibular-neuronitis/background-information/definition/","result":{"pageContext":{"chapter":{"id":"8ab4ebcd-03e4-5892-9e29-aabb20cb8f45","slug":"definition","fullItemName":"Definition","depth":2,"htmlHeader":"<!-- begin field f6dbc4a2-b1ab-414d-9084-b78a0607690b --><h2>What is it?</h2><!-- end field f6dbc4a2-b1ab-414d-9084-b78a0607690b -->","summary":"","htmlStringContent":"<!-- begin item 45f9e448-57e1-46a1-8e6b-f92d9324367d --><!-- begin field e5ee6eee-e037-4c2d-b383-edc23cc07bbb --><ul><li>Vestibular neuronitis (sometimes called vestibular neuritis) is a disorder characterised by acute, isolated, spontaneous, and prolonged vertigo of peripheral origin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Jeong et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Royal and Vargas, 2013</a>].  </li><li>The terms 'vestibular neuronitis' and 'labyrinthitis' have been used interchangeably in the past, but specific terminology is now recommended by experts [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Royal and Vargas, 2013</a>].  <ul><li>Vestibular neuronitis is thought to be due to inflammation of the vestibular nerve and may occur after a viral infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Royal and Vargas, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Wipperman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Dommaraju and Perera, 2016</a>].  </li><li>Labyrinthitis is a different diagnosis that involves inflammation of the labyrinth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Kaski and Bronstein, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Dommaraju and Perera, 2016</a>]. Hearing loss is a feature of labyrinthitis, but hearing is <em>not </em>affected in vestibular neuronitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Goddard and Fayad, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Greco et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Royal and Vargas, 2013</a>]. For more information on the management of labyrinthitis, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/vertigo/\">Vertigo</a>.</li></ul></li></ul><!-- end field e5ee6eee-e037-4c2d-b383-edc23cc07bbb --><!-- end item 45f9e448-57e1-46a1-8e6b-f92d9324367d -->","topic":{"id":"4161326f-3a9d-549b-a377-dc2f2a6f809a","topicId":"d53e1081-ae57-4dcc-8ee8-14e6be6fb3d6","topicName":"Vestibular neuronitis","slug":"vestibular-neuronitis","lastRevised":"Last revised in November 2017","chapters":[{"id":"1371e2f5-4cd3-5674-aae3-79470e21b62b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cb3f7155-69a7-5a7f-b8c1-2a1a113f0070","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a45dcd81-fea0-598a-ba01-782b350ffabd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06a83e39-ba88-5cb5-872a-7b5e56e06a3c","slug":"changes","fullItemName":"Changes"},{"id":"c9683178-6f5b-5445-a2d4-02d27c379f4b","slug":"update","fullItemName":"Update"}]},{"id":"a9baddc3-bb87-54e7-b6bf-fb890ce8d86d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"65c0b807-ad55-5cb6-8ac0-1beaf353fd29","slug":"goals","fullItemName":"Goals"},{"id":"c577b7a6-4f03-5974-a443-32000f43d67c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"300cd325-7e03-5d62-afb6-803945166705","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e3892d6-0403-52e9-a509-fc65bd12340b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c67ef3c1-dad6-5fbc-9fc2-1f9ef2f8fcef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e83fe4f4-878e-59eb-a20b-f35218ed5023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4fd633a-c05b-5b41-9dc2-d862bc4286b5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8ab4ebcd-03e4-5892-9e29-aabb20cb8f45","slug":"definition","fullItemName":"Definition"},{"id":"552f3d90-3666-593b-b806-28115dcd8f3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1966c14e-e128-5b21-bbce-6b9d4f48924d","slug":"complications","fullItemName":"Complications"},{"id":"f30ad763-2643-586e-9d19-cffd5f45d021","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"adbff71b-d255-5959-953d-3b2788094c8b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"081f5ce9-172b-5beb-9ace-bbe7a9e86705","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ba7e323e-e894-5821-9164-ea7cd07a38b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7c05a5c3-6c86-5daa-aed5-df8280f3723a","fullItemName":"Management","slug":"management","subChapters":[{"id":"f6abc1bb-cef0-5ec3-abe6-ca99c3f79fa7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"1ae90a52-6113-534c-8cf7-46d78bb039a3","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"354fa7f8-799b-53ab-900a-b4083df52ec8","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"4df87a4b-4d5c-56b0-b766-c143a60b38e8","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"ac9da5a7-a091-516f-a6b1-03ed2d2f7156","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"9f00019c-78be-54da-b9cb-69c6c04c5063","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c39d54c3-45ec-52b9-9dd2-efc3f3caa200","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d04e0140-1610-5826-9319-63f03c35c2d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"763af5f7-891e-5c76-9970-ae093e35ae7b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d0088dd9-7199-53a5-a4d0-e4299a54c061","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c9ae115f-4e3a-5af0-870e-16c967836515","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"27450791-3a41-5a8d-951b-efe744ca7944","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49115179-8551-5f4b-9d71-06a60c3445da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d4fd633a-c05b-5b41-9dc2-d862bc4286b5","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}